Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates a steady flow of news across diagnostics, medical devices, nutritionals and branded generic medicines, reflecting its role as a global healthcare company serving people in more than 160 countries. News coverage on this page highlights regulatory milestones, product launches, clinical data, corporate actions and community initiatives that shape Abbott’s business and its impact on patients.
Recent announcements include FDA approvals and clearances for cardiovascular and structural heart technologies, such as the Volt PFA System for treating atrial fibrillation and the Amplatzer Piccolo Delivery System for minimally invasive closure of patent ductus arteriosus in premature infants. Abbott also reports developments in diabetes care and metabolic health, including enhancements to its Libre app through the Libre Assist feature, which uses generative AI and continuous glucose monitoring data to help people living with diabetes understand how food choices may affect glucose levels, and the expansion of its Lingo over-the-counter continuous glucose monitor to additional mobile platforms.
Investors and observers will also find news about Abbott’s nutrition business, such as new Ensure Max Protein shakes aimed at supporting muscle health for active and older adults, as well as information on public health partnerships and community programs like the "We Give Blood" competition with the Big Ten Conference and the HeartMates community for people with heart health challenges. Corporate updates include dividend declarations and increases, as well as the announced Agreement and Plan of Merger to acquire Exact Sciences Corporation, which would expand Abbott’s presence in cancer screening and precision oncology diagnostics.
This news feed provides a centralized view of Abbott’s latest announcements, allowing readers to follow developments in its key business segments and understand how new products, regulatory events and strategic transactions may influence the company over time.
Abbott (NYSE: ABT) agreed to acquire Exact Sciences (NASDAQ: EXAS) for $105 per share, implying approximately $21 billion equity value and an estimated $23 billion enterprise value; Abbott will absorb about $1.8 billion of Exact Sciences net debt. Exact Sciences is projected to generate more than $3 billion in revenue this year with high‑teens organic growth and brings leading assets including Cologuard, Oncotype DX, Oncodetect and Cancerguard. Abbott expects the deal to be immediately accretive to revenue growth and gross margin. Closing is expected in Q2 2026, subject to shareholder and regulatory approvals.
Abbott (NYSE: ABT) and Hallmark Channel partner on a new holiday film, "The More the Merrier", which premieres Friday, Nov. 28, 2025 at 8 p.m. ET/PST and streams on Hallmark+ the following day. The movie features real members of Abbott HeartMates — a support community for people affected by heart conditions — and includes cameos by HeartMates ambassador Damar Hamlin.
The story centers on a 14-year-old heart patient inspired by HeartMates member Zeke Mankins; other featured members include Tony Daly, Jaden Hartley, Rian Krauth, and MacKenzie Maddry. Abbott cardiologists consulted on the script for medical accuracy. Safety links for specific Abbott devices are provided for U.S. audiences.
Abbott (NYSE: ABT) reported 3Q25 sales $11.37B, up 6.9% reported and 5.5% organic (or 7.5% organic excluding COVID‑19 tests). 3Q GAAP diluted EPS was $0.94; adjusted diluted EPS was $1.30. Reported operating margin was 18.1%; adjusted operating margin was 23.0% (+40 bps).
Medical Devices led growth: +14.8% reported and Diabetes Care CGM sales were $2.0B (+20.5% reported). Diagnostics declined: −6.6% reported (COVID testing sales $69M vs. $265M prior year). Abbott reaffirmed full‑year 2025 organic sales guidance and narrowed adjusted EPS range to $5.12–$5.18.
Abbott (NYSE:ABT) has scheduled its third-quarter 2025 financial results announcement for Wednesday, October 15, 2025, before market opening. The company will host a live earnings conference call at 8 a.m. Central time (9 a.m. Eastern). Investors can access the webcast through Abbott's Investor Relations website. An archived version of the call will be made available later the same day.
Abbott (NYSE: ABT) has announced its 407th consecutive quarterly dividend of 59 cents per share. The dividend will be payable on November 17, 2025, to shareholders of record as of October 15, 2025.
The company has demonstrated remarkable dividend consistency, having increased its dividend payout for 53 consecutive years. Abbott's commitment to dividend growth has earned it a place in the S&P 500 Dividend Aristocrats Index, which recognizes companies with at least 25 years of consecutive dividend increases.
Abbott (NYSE:ABT) has received CE Mark approval for an expanded indication of its Navitor™ TAVI system to treat patients with symptomatic, severe aortic stenosis who are at low or intermediate surgical risk. This expansion, supported by the VANTAGE trial data, makes Navitor available across all surgical risk categories in Europe.
The VANTAGE study demonstrated excellent outcomes, including a low 2.3% rate of all-cause mortality or fatal stroke/stroke with disability, no moderate or greater PVL at 30 days, and a 97% technical success rate. Additionally, the European Society of Cardiology announced updated guidelines upgrading recommendations for Abbott's MitraClip™ and TriClip™ therapies for treating heart valve diseases.
Abbott (NYSE:ABT) and the Big Ten Conference have launched Year 2 of their 'We Give Blood' drive competition, running from August 27 to December 5, 2025. The nationwide challenge involves all 18 Big Ten universities competing to inspire the most blood donations, with the winning school receiving $1 million from Abbott for student or community health initiatives.
The campaign addresses critical U.S. blood shortages, with some centers reporting less than one-day supply. Abbott is offering exclusive limited-edition Homefield designed T-shirts and hosting 12 Weekly One-Up Challenges during the football season. The University of Nebraska-Lincoln won the inaugural 2024 competition with nearly 4,000 donors, saving up to 12,000 lives. The 2025 winner will be announced at the Big Ten Championship Football Game on December 6 in Indianapolis.
Abbott (NYSE: ABT) reported strong second-quarter 2025 results with reported sales growth of 7.4% and organic sales growth of 7.5% excluding COVID-19 testing. The company achieved GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.26, reflecting double-digit growth year-over-year.
Key financial metrics include improved margins, with reported gross margin at 52.7% and adjusted gross margin at 57.0%, representing a 100 basis point increase. The company projects full-year 2025 organic sales growth of 7.5-8.0% excluding COVID-19 testing and adjusted diluted EPS of $5.10-$5.20.
Notable developments include FDA approval of the Tendyne™ TMVR system, completion of enrollment in the FlexPulse U.S. IDE trial, and plans for a new cardiovascular device manufacturing facility in Georgia by 2028. The company also declared its 406th consecutive quarterly dividend of $0.59 per share.
Abbott (NYSE:ABT) has scheduled its second-quarter 2025 financial results announcement for Thursday, July 17, 2025, before market opening. The company will host a live earnings conference call at 8 a.m. Central time (9 a.m. Eastern). Investors can access the webcast through Abbott's Investor Relations website at www.abbottinvestor.com. An archived version of the call will be made available later the same day.
FAQ
What is the current stock price of Abbott Labs (ABT)?
What is the market cap of Abbott Labs (ABT)?
